09:21 AM EDT, 03/16/2026 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said in a regulatory filing Monday that it intends to stop dosing and enrollment in its phase 2 studies for Voxzogo in Turner syndrome, SHOX-deficiency and Aggrecan-deficiency due to the occurrence of "several" events of slipped capital femoral epiphysis, a hip disorder, in two current trials.

The company's phase 2 Canopy studies of Voxzogo in children with Noonan syndrome and those with idiopathic short stature without Aggrecan-deficiency will continue as planned, BioMarin said in its 8-K filing with the US Securities and Exchange Commission.

Shares of the company were down 3.3% in premarket activity Monday.